今年双11，淘宝首次在全球20个国家和地区同步启动大促，并以中、英、俄、泰、马来五种语言服务全球消费者。 双11全周期，淘宝在新加坡、马来西亚、澳大利亚、日本等十多个境外市场实现GMV强劲增长，双11加速从"中国购物节"蜕变为全球消费者的节日。 出海为淘系商家创造了巨大的增量。数据显示，双11期间，蕉内、亚朵星球、可复美、珀莱雅等数十个品牌境外成交额破千万。淘宝推出的"出海增长计 划"帮助商家0门槛出海，获得超额的海外增长回报，超过20万签约商家成交额实现翻倍增长，其GMV增幅更是淘宝出海整体大盘的三倍。 过去一年，淘宝出海不断加强出海"基础建设"。随着物流、支付、本地化运营能力的全面提升，海外消费者也正以前所未有的热情积极参与双11。双11期 间，淘宝境外日下单用户数（DAC）实现双位数增长；其中9个重点市场，日下单用户数同比增幅更超过20%，显示出这些区域作为高潜力出海目的地的巨 大价值。 今年以来，淘宝还推出了多种外语版本，显著降低了非中文用户的使用门槛，吸引了大量的海外本土消费者。双11当天，澳大利亚与新加坡英文用户成交都 创下了历史新高；在通用俄语的哈萨克斯坦，30%的新增购买用户通过俄语界面完成下 ...

Core Insights - This year's Double 11 event marked the first time Taobao launched globally across 20 countries and regions, providing services in five languages, resulting in strong GMV growth in overseas markets [1][2] - The number of daily active users (DAC) from overseas markets saw double-digit growth, with nine key markets experiencing over 20% year-on-year increases, indicating significant potential in these regions [1] Group 1 - During the Double 11 period, dozens of brands achieved over 10 million in overseas transactions, with more than 200,000 signed merchants doubling their transaction volumes, outpacing the overall growth rate of Taobao's international business by three times [1] - Taobao's introduction of multiple foreign language versions has lowered the usage barrier for non-Chinese users, attracting a large number of local overseas consumers [1] - On Double 11 day, English-speaking users in Australia and Singapore achieved record transaction highs, while 30% of new purchasing users in Kazakhstan completed orders through the Russian interface [1] Group 2 - Taobao's first-time launch of direct mail services for furniture successfully addressed the "last mile" challenge for large goods, while other self-operated businesses like Ali Health and Fliggy also initiated overseas services [2] - The cross-border free shipping trial for perishable food in Hong Kong resulted in over 50% year-on-year growth in transaction volume, highlighting the potential for more industries and merchants to benefit from overseas growth opportunities [2] - Taobao's overseas general manager emphasized that Double 11 serves as a crucial "barometer" for the Chinese e-commerce industry, with this year's event achieving local consumer engagement, diverse supply offerings, and global fulfillment [2]

Trade and Economic Performance - In the first ten months of 2025, China's total goods trade value reached 37.31 trillion yuan, reflecting a year-on-year growth of 3.6% [1] - Exports amounted to 22.12 trillion yuan, increasing by 6.2%, while imports were 15.19 trillion yuan, remaining stable compared to the previous year [1] Trade Partnerships - ASEAN became China's largest trading partner, with a trade value of 6.18 trillion yuan, growing by 9.1% and accounting for 16.6% of China's total foreign trade [2] - The EU ranked second with a trade value of 4.88 trillion yuan, up by 4.9%, representing 13.1% of the total [2] - The US fell to third place, with a trade value of 3.38 trillion yuan, down by 15.9%, making up 9% of the total [2] - Trade with Belt and Road Initiative countries totaled 19.28 trillion yuan, marking a growth of 5.9% [2] Automotive Industry - Chinese automotive brands saw a significant increase in sales in the UK, with a 235% year-on-year rise in September, totaling 40,729 units sold [3] - From January to September, cumulative sales reached 142,684 units, a 91% increase [3] - BYD's sales in the UK for September reached 11,271 units, surging by 880% [3] Technology and Innovation - Alibaba's Amap announced a partnership with XPeng Motors to integrate Robotaxi services into its platform, marking a significant step in autonomous driving technology [4] - This collaboration aims to create the largest Robotaxi aggregation platform globally [4] E-commerce Trends - During the first week of the Double 11 shopping festival, the health sector on Taobao experienced double-digit growth in overseas transactions, with significant demand for dietary supplements and traditional health products [5] - Alibaba Health Pharmacy entered the overseas market, adding nearly 150,000 quality products [5] Global App Performance - Temu achieved over 1.2 billion downloads globally by October 2025, maintaining its position as the top shopping app for three consecutive years [6] Logistics and Delivery Services - UPS announced a 5.9% increase in shipping rates effective December 22, 2025, with FedEx planning a similar adjustment in January 2026 [7] Automotive Investments - Geely acquired a 26.4% stake in Renault's Brazilian operations, enabling local production and market expansion in Latin America [8] - BYD plans to launch its luxury brand "Yangwang" in the Middle East in early 2026, with subsequent expansions to Europe and the Americas [9]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][7]. Core Views - The internet healthcare sector is entering a stable growth phase, with online pharmaceutical retail penetration expected to accelerate. Non-pharmaceutical products like nutritional supplements and home medical devices are well-suited for online retail, while the pharmaceutical market's online penetration is still low but poised for growth due to changing consumer behaviors and regulatory support [6][27][30]. Financial Data and Profit Forecast - The company is projected to achieve revenues of RMB 27,026.56 million in FY2024, increasing to RMB 39,029.33 million by FY2028, reflecting a revenue growth rate of 0.98% in FY2024 and an average of 8.33% from FY2025 to FY2028 [2]. - Adjusted net profit is expected to rise from RMB 1,438.27 million in FY2024 to RMB 3,355.45 million by FY2028, with a significant growth rate of 91.64% in FY2024 [2]. - The report anticipates a gradual improvement in gross margin from 21.81% in FY2024 to 25.85% in FY2028, alongside an increase in return on equity (ROE) from 6.07% to 13.00% over the same period [2]. Company Overview - The company operates in three main segments: 1P pharmaceutical self-operated business, 3P pharmaceutical e-commerce platform business, and innovative healthcare and digital services [17]. - The self-operated pharmaceutical business accounted for 85.4% of the company's revenue in FY2025, while the e-commerce platform business contributed 11.7% [17]. Market Trends - The report highlights a favorable regulatory environment for online healthcare, with policies gradually promoting online medical insurance coverage and the legitimacy of internet hospitals [27][28]. - The penetration rates for nutritional supplements and home medical devices are increasing, while the pharmaceutical sector is expected to see rapid growth in online retail penetration due to evolving consumer preferences and regulatory changes [30][31]. Competitive Landscape - The competition in the internet healthcare sector is expected to stabilize, with a clear distinction emerging between B2C and O2O models. The report notes that while O2O instant retail will continue to grow, its penetration in certain product categories may remain limited [45][49]. Innovation and Growth Opportunities - The company is actively exploring AI applications in healthcare, enhancing operational efficiency and developing AI-assisted diagnostic tools. This strategic focus on AI is expected to improve service delivery and patient outcomes [52][58]. - The report also mentions the company's cloud hospital and digital service initiatives, which are anticipated to provide significant growth opportunities in the future [52].

Core Viewpoint - Alibaba Health reported strong financial results for the fiscal year 2025, marking the third consecutive year of revenue and net profit growth, driven by increased user engagement and innovation in its business model [1][2][4]. Financial Performance - For the fiscal year 2025, Alibaba Health achieved a revenue of 30.598 billion yuan, representing a year-on-year growth of 13.2% [2]. - The net profit for the same period was 1.432 billion yuan, showing a significant increase of 62.2% year-on-year [2]. - Adjusted net profit reached 1.95 billion yuan, up 35.6% compared to the previous year [1][2]. Historical Performance - Alibaba Health's revenue has shown a consistent upward trend, increasing from 9.596 billion yuan in fiscal year 2020 to 30.598 billion yuan in fiscal year 2025 [3]. - The net profit has fluctuated but generally trended upwards, from a loss of 6.586 million yuan in fiscal year 2020 to a profit of 1.432 billion yuan in fiscal year 2025 [3]. Business Development - The company has enhanced its one-stop healthcare service capabilities, focusing on improving user experience through better product offerings and services [4]. - The Tmall Health platform has seen steady growth, with a significant increase in annual GMV and active users, and the number of online products grew by over 91% to 133 million [4]. Investment in Innovation - Alibaba Health invested 720 million yuan in product development during fiscal year 2025, focusing on AI technology, business optimization, and digital traceability [5]. - The company’s self-operated pharmaceutical business generated over 26.124 billion yuan in revenue, reflecting a year-on-year growth of 10% [5]. Market Position and Stock Performance - Alibaba Health's stock price saw a cumulative increase of over 60% in February and March due to the recovery of the Hong Kong tech sector and interest in AI healthcare concepts, but has since declined [7]. - As of May 20, the stock price was 4.89 HKD per share, with a total market capitalization of 78.7 billion HKD [7].